CryoLife (CRY) Tops Q4 EPS by 2c

CryoLife (NYSE: CRY) reported Q4 EPS of $0.10, $0.02 better than the analyst estimate of $0.08. Revenue for the quarter came in at $69.7 million versus the consensus estimate of $70.82 million.

"The fourth quarter was marked by significant progress on our key initiatives, highlighted by European approvals for two next generation JOTEC products, E-nside and E-nya, the approval to commence the PROACT Xa trial to study the use of Eliquis® with the On-X Aortic Valve, the initial launch of NEXUS™ into select European markets, as well as our collaboration with Misonix," said Pat Mackin, Chairman, President, and Chief Executive Officer. "Additionally, we anticipate the approval for E-vita OPEN NEO in the first quarter of 2020, and we continue to increase JOTEC and vascular tissue supply. The full launch in 2020 of three next generation JOTEC products and NEXUS, as well as the commencement of the PROACT Xa trial, positions us well to deliver high single-digit revenue growth over the next several years."

For earnings history and earnings-related data on CryoLife (CRY) click here.

You May Also Be Interested In

• Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
• L3Harris Technologies (LHX) Tops Q1 EPS by 15c; raises guidance
• AptarGroup (ATR) Tops Q1 EPS by 11c